Bedminster, N.J.-based Aerie Pharmaceuticals is looking to raise $57.5 million from an initial public offering, according to an Xconomy report.
Aerie plans to use the money for supporting and promoting its glaucoma drug candidate through clinical trials. The company has raised $63.5 million from investors since it was founded in 2005.
More Articles on Ophthalmology:
5 Ways Healthcare Reform Will Impact Ophthalmologists
Ophthalmic Laser Company Lumenis Receives FDA 510(k) Approval
Ophthalmologist Dr. Benjamin Hale Joins Geisinger Health System in Pennsylvania
Aerie plans to use the money for supporting and promoting its glaucoma drug candidate through clinical trials. The company has raised $63.5 million from investors since it was founded in 2005.
More Articles on Ophthalmology:
5 Ways Healthcare Reform Will Impact Ophthalmologists
Ophthalmic Laser Company Lumenis Receives FDA 510(k) Approval
Ophthalmologist Dr. Benjamin Hale Joins Geisinger Health System in Pennsylvania